PA5-20721

antibody from Invitrogen Antibodies

Targeting: APOA1

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-20721

Provider

Invitrogen Antibodies

Product name

ApoA1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control is human liver tissue lysate. PA5-20721 can be used with blocking peptide PEP-0835.

Reactivity

Human, Mouse, Rat

Host

Chicken/Avian

Isotype

IgY

Vial size

100 μg

Concentration

1 mg/mL

Storage

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

References

Submitted references

Activation of neutral sphingomyelinase 2 through hyperglycemia contributes to endothelial apoptosis via vesicle-bound intercellular transfer of ceramides.

Zietzer A, Jahnel AL, Bulic M, Gutbrod K, Düsing P, Hosen MR, Dörmann P, Werner N, Nickenig G, Jansen F
Cellular and molecular life sciences : CMLS 2021 Dec 24;79(1):48

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of human liver cells using a ApoA1 polyclonal antibody (Product # PA5-20721) at a 20 µg/mL dilution.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ApoA1 in mouse liver tissue with ApoA1 Polyclonal Antibody (Product # PA5-20721) at 20 µg/mL. Red: ApoA1 Blue: DAPI staining

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ApoA1 in human liver tissue with ApoA1 Polyclonal Antibody (Product # PA5-20721) at 20 µg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 1 A Schematic diagram of the lEV isolation protocol. B Flow-cytometric analysis of apoptosis induction in HCAECs after hyperglycemic injury, n = 6, with representative dot blots. C MTT viability assay in HCAECs after hyperglycemic injury, n = 6. D + E Distribution of lEV size and relative lEVs released after hyperglycemic injury in HCAECs, as analyzed by nanoparticle tracking analysis, n = 3. F Direct electron microscopic imaging of HCAEC-derived lEVs with negative staining, representative image. G Characterization of lEVs by immunoblotting for Flotillin-1, beta -Actin, Annexin V, GRP94, Actinin-4, TSG101, Apolipoprotein A1, Apolipoprotein B100 (with additional human plasma as an antibody control). H Mass spectrometric analysis of ceramides in HCAECs and lEVs after hyperglycemic injury. All data are presented as individual experiments with the mean +- SEM; n.s. not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001. ANOVA + Bonferoni's multiple comparison test were used for B + C , unpaired t -Test for E , two-way ANOVA + Bonferoni's multiple comparison test were used for H